Cargando…
Treatment of Peritoneal Surface Malignancies by Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Spain: Results of the National Registry of the Spanish Group of Peritoneal Oncologic Surgery (REGECOP)
Introduction: Treatment of Peritoneal Surface Malignancies (PSM) with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has achieved results never seen before in these patients, which classically have a poor prognosis. The possibility of conducting clinical trials in...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253421/ https://www.ncbi.nlm.nih.gov/pubmed/37297969 http://dx.doi.org/10.3390/jcm12113774 |
_version_ | 1785056401909874688 |
---|---|
author | Manzanedo, Israel Pereira, Fernando Cascales-Campos, Pedro Muñoz-Casares, Cristobal Asensio, Enrique Torres-Melero, Juan Prada-Villaverde, Arancha Caravaca-García, Ibán Gutiérrez-Calvo, Alberto Vaqué, Javier Ortega, Gloria Titos-García, Alberto González-Sánchez, Laura Pérez-Viejo, Estíbalitz Serrano, Ángel Martínez-Torres, Beatriz |
author_facet | Manzanedo, Israel Pereira, Fernando Cascales-Campos, Pedro Muñoz-Casares, Cristobal Asensio, Enrique Torres-Melero, Juan Prada-Villaverde, Arancha Caravaca-García, Ibán Gutiérrez-Calvo, Alberto Vaqué, Javier Ortega, Gloria Titos-García, Alberto González-Sánchez, Laura Pérez-Viejo, Estíbalitz Serrano, Ángel Martínez-Torres, Beatriz |
author_sort | Manzanedo, Israel |
collection | PubMed |
description | Introduction: Treatment of Peritoneal Surface Malignancies (PSM) with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has achieved results never seen before in these patients, which classically have a poor prognosis. The possibility of conducting clinical trials in these diseases is complicated, since some of them are rare, so the analysis of large databases provides very valuable scientific information. The aim of this study is to analyze the global results of the National Registry of the Spanish Group of Peritoneal Oncologic Surgery (REGECOP), whose objective is to register all patients scheduled for HIPEC nationwide. Methods: This is a retrospective analysis of the data recorded in the REGECOP from 36 Spanish hospitals from 2001 to 2021. There were 4159 surgical interventions in 3980 patients. Results: 66% are women and 34% are men with a median age of 59 years (range 17–86). 41.5% of the patients were treated for Peritoneal Metastases (PM) of colorectal cancer (CRC); 32.4% were women with ovarian cancer (OC) with PM; 12.8% were treated for pseudomyxoma peritonei (PMP); 6.2% had PM from gastric cancer (GC); 4.9% had PM of non-conventional origin; and, finally, 2.1% of cases were patients diagnosed with peritoneal mesothelioma. The median Peritoneal Cancer Index (PCI) was 9 (0–39), and complete cytoreduction was achieved in 81.7% of the procedures. Severe morbidity (Dindo–Clavien grade III–IV) was observed in 17.7% of surgeries, with 2.1% mortality. Median hospital stay was 11 days (0–259). Median overall survival (OS) was 41 months for CRC patients, 55 months for women with OC, was not reached in PMP patients, was 14 months for GC patients, and 66 months in mesothelioma patients. Conclusions: large databases provide extremely useful data. CRS with HIPEC in referral centers is a safe treatment with encouraging oncologic results in PSM. |
format | Online Article Text |
id | pubmed-10253421 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102534212023-06-10 Treatment of Peritoneal Surface Malignancies by Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Spain: Results of the National Registry of the Spanish Group of Peritoneal Oncologic Surgery (REGECOP) Manzanedo, Israel Pereira, Fernando Cascales-Campos, Pedro Muñoz-Casares, Cristobal Asensio, Enrique Torres-Melero, Juan Prada-Villaverde, Arancha Caravaca-García, Ibán Gutiérrez-Calvo, Alberto Vaqué, Javier Ortega, Gloria Titos-García, Alberto González-Sánchez, Laura Pérez-Viejo, Estíbalitz Serrano, Ángel Martínez-Torres, Beatriz J Clin Med Article Introduction: Treatment of Peritoneal Surface Malignancies (PSM) with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has achieved results never seen before in these patients, which classically have a poor prognosis. The possibility of conducting clinical trials in these diseases is complicated, since some of them are rare, so the analysis of large databases provides very valuable scientific information. The aim of this study is to analyze the global results of the National Registry of the Spanish Group of Peritoneal Oncologic Surgery (REGECOP), whose objective is to register all patients scheduled for HIPEC nationwide. Methods: This is a retrospective analysis of the data recorded in the REGECOP from 36 Spanish hospitals from 2001 to 2021. There were 4159 surgical interventions in 3980 patients. Results: 66% are women and 34% are men with a median age of 59 years (range 17–86). 41.5% of the patients were treated for Peritoneal Metastases (PM) of colorectal cancer (CRC); 32.4% were women with ovarian cancer (OC) with PM; 12.8% were treated for pseudomyxoma peritonei (PMP); 6.2% had PM from gastric cancer (GC); 4.9% had PM of non-conventional origin; and, finally, 2.1% of cases were patients diagnosed with peritoneal mesothelioma. The median Peritoneal Cancer Index (PCI) was 9 (0–39), and complete cytoreduction was achieved in 81.7% of the procedures. Severe morbidity (Dindo–Clavien grade III–IV) was observed in 17.7% of surgeries, with 2.1% mortality. Median hospital stay was 11 days (0–259). Median overall survival (OS) was 41 months for CRC patients, 55 months for women with OC, was not reached in PMP patients, was 14 months for GC patients, and 66 months in mesothelioma patients. Conclusions: large databases provide extremely useful data. CRS with HIPEC in referral centers is a safe treatment with encouraging oncologic results in PSM. MDPI 2023-05-31 /pmc/articles/PMC10253421/ /pubmed/37297969 http://dx.doi.org/10.3390/jcm12113774 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Manzanedo, Israel Pereira, Fernando Cascales-Campos, Pedro Muñoz-Casares, Cristobal Asensio, Enrique Torres-Melero, Juan Prada-Villaverde, Arancha Caravaca-García, Ibán Gutiérrez-Calvo, Alberto Vaqué, Javier Ortega, Gloria Titos-García, Alberto González-Sánchez, Laura Pérez-Viejo, Estíbalitz Serrano, Ángel Martínez-Torres, Beatriz Treatment of Peritoneal Surface Malignancies by Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Spain: Results of the National Registry of the Spanish Group of Peritoneal Oncologic Surgery (REGECOP) |
title | Treatment of Peritoneal Surface Malignancies by Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Spain: Results of the National Registry of the Spanish Group of Peritoneal Oncologic Surgery (REGECOP) |
title_full | Treatment of Peritoneal Surface Malignancies by Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Spain: Results of the National Registry of the Spanish Group of Peritoneal Oncologic Surgery (REGECOP) |
title_fullStr | Treatment of Peritoneal Surface Malignancies by Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Spain: Results of the National Registry of the Spanish Group of Peritoneal Oncologic Surgery (REGECOP) |
title_full_unstemmed | Treatment of Peritoneal Surface Malignancies by Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Spain: Results of the National Registry of the Spanish Group of Peritoneal Oncologic Surgery (REGECOP) |
title_short | Treatment of Peritoneal Surface Malignancies by Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Spain: Results of the National Registry of the Spanish Group of Peritoneal Oncologic Surgery (REGECOP) |
title_sort | treatment of peritoneal surface malignancies by cytoreductive surgery (crs) and hyperthermic intraperitoneal chemotherapy (hipec) in spain: results of the national registry of the spanish group of peritoneal oncologic surgery (regecop) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253421/ https://www.ncbi.nlm.nih.gov/pubmed/37297969 http://dx.doi.org/10.3390/jcm12113774 |
work_keys_str_mv | AT manzanedoisrael treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop AT pereirafernando treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop AT cascalescampospedro treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop AT munozcasarescristobal treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop AT asensioenrique treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop AT torresmelerojuan treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop AT pradavillaverdearancha treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop AT caravacagarciaiban treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop AT gutierrezcalvoalberto treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop AT vaquejavier treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop AT ortegagloria treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop AT titosgarciaalberto treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop AT gonzalezsanchezlaura treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop AT perezviejoestibalitz treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop AT serranoangel treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop AT martineztorresbeatriz treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop AT treatmentofperitonealsurfacemalignanciesbycytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecinspainresultsofthenationalregistryofthespanishgroupofperitonealoncologicsurgeryregecop |